Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Safe Cosmetics Act Launches, Aimed At “Regulatory Black Hole”

Executive Summary

House democrats Markey and Schakowsky have reintroduced The Safe Cosmetics and Personal Care Products Act. The legislation, backed by the Campaign for Safe Cosmetics, claims to close loopholes in federal law to ensure that consumers are not exposed to carcinogens and other hazardous substances through cosmetics use.


Related Content

Cosmetics Firms To Phase Out Cocamide DEA Under Prop 65 Settlements
Cruelty Free Int’l Working With Rep. Schakowsky On Animal Alternatives
Study Projecting Rise In Animal Tests Casts Pall On Safe Cosmetics Act
Campaign For Safe Cosmetics Targets Industry, Retailer “Laggards” In 2014
PCPC, FDA Negotiate Oversight Bill With Possible State-Law Preemption
FDA Seeks $19 Mil. From Cosmetics Firms In User-Fee-Heavy 2014 Budget
House Reps Request Clarification From FDA On Brazilian Blowout Status
Council-Approved Cosmetics Safety Bill Launches
Safe Cosmetics Act Would Remedy “Broken Regulatory System,” Says CFSC
Lawmakers Introduce Revamped Safe Cosmetics Act



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts